EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Patient-Reported Burden of Indolent Systemic Mastocytosis in a Managed Care Organization

Robert S Zeiger, Kevin Y Tse, Qiaowu Li, Mary Saparudin, Sahar S Al-Salman, Eric J Puttock, Kerri Miller, Dakota Powell, Benjamin Lampson, Erin Sullivan, Wansu Chen

The Journal of Allergy and Clinical Immunology: In Practice · 2025

DOI: 10.1016/j.jaip.2024.10.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Robert S Zeiger und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Kaiser Permanente Southern California, San Diego, Calif; Department of Research and Evaluation, Kaiser Permanente Southern Cal…. Hauptthemen laut MEDLINE: Mastocytosis, Systemic, Quality of Life, Cost of Illness. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Heart, Lung, and Blood Institute, Merck, Kaiser Permanente.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Indolent systemic mastocytosis (ISM), the most frequent subtype of systemic mastocytosis, requires better understanding. OBJECTIVE: To better understand the diagnostic journey, symptom severity, impact on quality of life and work/activities, and health care utilization of ISM. METHODS: Survey data were collected from 40 adults with documented ISM meeting World Health Organization 2016 criteria, including validated questionnaires (ISM Symptom Assessment Form [ISM-SAF] and Short Form Quality of Life Survey [SF-12v1]). Spearman correlation coefficients determined the associations between the ISM-SAF Total Symptom Score (TSS) and SF-12v1 scores. ISM burden was compared based on moderate/severe compared with mild TSS scores using Kruskal-Wallis and Fisher exact tests. RESULTS: Patients were aged 56.0 ± 13.0 years, 65.0% female, 62.5% White, and 22.5% Hispanic patients. ISM diagnosis took >2 years in 40%, required ≥6 visits in 47.5%, and was considered moderately/extremely difficult in 50% of patients. Nearly half experienced symptoms daily and rated severity somewhat/significantly worsened since diagnosis. The overall TSS was 27.4 ± 16.2 (mean ± standard deviation). SF-12 Physical Component Summary (PCS) (46.7 ± 11.4) and Mental Component Summary (MCS) (47.6 ± 10.2) scores were lower than the general population score of 50. Moderate correlations (P < .001) were found between TSS and the PCS (ρ = -0.6406; P < .001) and MCS (ρ = -0.5104; P < .001). Compared with patients with mild severity (TSS < 28; n = 21), patients with moderate/severe severity (TSS ≥ 28; n = 19) evidenced significantly higher skin and gastrointestinal symptom scores (both, P ≤ .001). ISM's impact on ability to work for pay was associated with TSS (P = .004). Symptom-directed treatment had limited effect. CONCLUSION: ISM was self-reported as a burdensome condition in half the patients that markedly affected daily living.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mastocytosis, SystemicQuality of LifeCost of IllnessHumansFemaleMaleMiddle AgedAdultAgedSurveys and QuestionnairesManaged Care ProgramsSeverity of Illness IndexPatient Reported Outcome Measures

Stichwörter der Autor:innen

Disease burdenHealth care resource utilizationIndolent systemic mastocytosisManaged carePatient-reported outcomesQuality of lifeSurvey

Autor:innen und Institutionen

  • Department of Allergy, Kaiser Permanente Southern California, San Diego, Calif; Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, Calif; Department of Clinical Science, Kaiser Perma…
  • Department of Allergy, Kaiser Permanente Southern California, San Diego, Calif.
  • Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, Calif.
  • Blueprint Medicines Corporation, Cambridge, Mass.

Förderung

  • National Heart, Lung, and Blood Institute
  • Merck
  • Kaiser Permanente

Zitieren

APA

Zeiger, R. S., Tse, K. Y., Li, Q., Saparudin, M., Al-Salman, S. S., Puttock, E. J., Miller, K., Powell, D., Lampson, B., Sullivan, E., & Chen, W. (2025). Patient-Reported Burden of Indolent Systemic Mastocytosis in a Managed Care Organization. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.10.021

Vancouver

Zeiger RS, Tse KY, Li Q, Saparudin M, Al-Salman SS, Puttock EJ, et al. Patient-Reported Burden of Indolent Systemic Mastocytosis in a Managed Care Organization. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2024.10.021

BibTeX
@article{Zeiger2025,
  author = {Zeiger, Robert S and Tse, Kevin Y and Li, Qiaowu and Saparudin, Mary and Al-Salman, Sahar S and Puttock, Eric J and Miller, Kerri and Powell, Dakota and Lampson, Benjamin and Sullivan, Erin and Chen, Wansu},
  title = {Patient-Reported Burden of Indolent Systemic Mastocytosis in a Managed Care Organization},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2025},
  doi = {10.1016/j.jaip.2024.10.021}
}
Kostenlos starten →